13924-95-3

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxypyrazine-2-carboxylic acid methyl ester is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason] its role as a metabolite of an established antibacterial drug, Pyrazinamide. This makes it a valuable compound for further research and development in the fight against bacterial infections, particularly tuberculosis.
Used in Research and Development:
In the field of scientific research, 5-Hydroxypyrazine-2-carboxylic acid methyl ester is used as a key compound for understanding the metabolic pathways and mechanisms of action of Pyrazinamide. This knowledge can lead to the development of new and improved anti-tuberculosis drugs, as well as a better understanding of the drug's efficacy and potential side effects.
Used in Drug Metabolism Studies:
5-Hydroxypyrazine-2-carboxylic acid methyl ester is utilized in drug metabolism studies to investigate how the body processes and eliminates Pyrazinamide. This information is crucial for optimizing drug dosages, minimizing toxicity, and enhancing the overall safety and effectiveness of the treatment.

InChI:InChI=1/C6H6N2O3/c1-11-6(10)4-2-8-5(9)3-7-4/h2-3H,1H3,(H,8,9)

Upstream product

• 67-56-1 methanol 
• 34604-60-9 5-hydroxypyrazinoic acid 
• 77168-76-4 3-carbamoyl-1,6-dihydro-6-oxo-2-pyrazinecarboxylic acid 
• 57005-60-4 1,6-dihydro-6-oxo-2,3-pyrazinedicarbonitrile 
• 13924-96-4 4,5-dihydro-5-oxo-2-pyrazinecarboxamide 
• 34604-60-9 4,5-dihydro-5-oxo-2-pyrazinecarboxylic acid 

Downstream Products

• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 
• 210037-58-4 5-bromopyrazine-2-carboxylic acid methyl ester 
• 38789-75-2 methyl 5-methoxypyrazine-2-carboxylate 
• 77168-80-0 5,6-dihydroxy-2-pyrazinecarboxylic acid 
• 1421502-62-6 [2-[6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl]-1 ,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl][5-(piperidin-1-yl)pyrazin-2-yl]methanone 
• 1421502-74-0 C₃₂H₂₅F₂N₇O₃ 
• 1421503-72-1 5-(2-fluoro-phenoxy)pyrazine-2-carboxylic acid methyl ester 
• 1017603-80-3 5-(piperidin-1-yl)pyrazine-2-carboxylic acid methyl ester 
• 1421502-64-8 {2-[6-(2-ethyl-5-fluoro-4-hydroxy-phenyl)-1H-indazol-3-yl]-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl}-(5-piperidin-1-yl-pyrazin-2-yl)methanone sodium salt 
• 1210707-88-2 5-(piperidin-1-yl)pyrazine-2-carboxylic acid 

Relevant academic research and scientific papers

N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS

Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, Xsu

NOVEL PHENYLPYRROLE DERIVATIVE

The present invention relates to a compound or a pharmacologically acceptable salt thereof having superior glucokinase activating activity, and is a compound represented by general formula (I), or pharmacologically acceptable salt thereof: [wherein, A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R2 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group α or a heterocyclic group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group α, R3 represents a hydroxy group or a C1-C6 alkoxy group, and Substituent Group α consists of, for example, a halogen atom, a C1-C6 alkyl group, a C1-C6 alkyl group substituted with 1 or 2 hydroxy group(s), a C1-C6 alkylsulfonyl group, and a group represented by the formula -V-NR5R6 (wherein, V represents a carbonyl group or a sulfonyl group, and R5 and R6 may be the same or different and respectively represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 together with the nitrogen atom bonded thereto form a 4- to 6-membered saturated heterocycle that may be substituted with 1 or 2 group(s) independently selected from a C1-C6 alkyl group and a hydroxy group, and the 4- to 6-membered saturated heterocycle may further contain one oxygen atom or nitrogen atom)].

AMIDE DERIVATIVES AND DRUGS

The present invention provides an amide derivative represented by the following formula [1]: wherein n represents 0 or 1; X represents CR4 or N; Y represents CR6 or N; Z represents CR7 or N; R1 and R2 may be the same or different and each represents hydrogen, optionally substituted alkyl, acyl, optionally substituted aryl, or an optionally substituted aromatic heterocyclic group; R4, R5, R6 and R7 may be the same or different and each represents hydrogen, halogen, hydroxy, amino, alkyl, haloalkyl, alkoxy, monoalkylamino, dialkylamino, arylalkyl, cyano, or nitro; and R3 represents optionally substituted alkylamino, optionally substituted arylamino, or optionally substituted cyclic amino, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising them as an active ingredient. The compound of the present invention is useful as a TGF-β inhibitor.